Eli Lilly & Co. has described pyrrolidine compounds targeting apolipoprotein(a) (Apo[a]) and acting as lipoprotein(a)-lowering agents reported to be useful for the treatment of cardiovascular disorders.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, neurodegeneration, neuroinflammation, pain and psychiatric disorders.

Vivace Therapeutics Inc. has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, polycystic kidney and hepatic fibrosis.

Xinthera Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of brain cancer.

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed fused heterocyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis and inflammatory disorders, among others.

Beijing Entaiwei Medicine Science Technology Co. Ltd. has described prodrugs of β-D-N4-hydroxycytidine reported to be useful for the treatment of viral infections.

Medshine Discovery Inc. has divulged GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shandong New Time Pharmaceutical Co. Ltd. has identified cathepsin K inhibitors reported to be useful for the treatment of osteoporosis, among others.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors, preferably PARP-1, reported to be useful for the treatment of cancer.

Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed sodium channel protein type 10 subunit alpha (Nav1.8) channel blockers reported to be...